RU2771292C2 - Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения - Google Patents

Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения Download PDF

Info

Publication number
RU2771292C2
RU2771292C2 RU2020115713A RU2020115713A RU2771292C2 RU 2771292 C2 RU2771292 C2 RU 2771292C2 RU 2020115713 A RU2020115713 A RU 2020115713A RU 2020115713 A RU2020115713 A RU 2020115713A RU 2771292 C2 RU2771292 C2 RU 2771292C2
Authority
RU
Russia
Prior art keywords
seq
sequence
antibody
conjugated
activated
Prior art date
Application number
RU2020115713A
Other languages
English (en)
Russian (ru)
Other versions
RU2020115713A3 (https=
RU2020115713A (ru
Inventor
Швета Сингх
Дженнифер Хоуп РИЧАРДСОН
Лора Паттерсон СЕРВЕР
Джонатан Александр Терретт
Сьюзан Э. МОРГАН-ЛЭПП
Трейси ЭНРИКЕС
Шерри Л. РАЛСТОН
Марвин Роберт ЛЕАННА
Илария БАДАНЬЯНИ
Сахана БОУЗ
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of RU2020115713A publication Critical patent/RU2020115713A/ru
Publication of RU2020115713A3 publication Critical patent/RU2020115713A3/ru
Application granted granted Critical
Publication of RU2771292C2 publication Critical patent/RU2771292C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2020115713A 2017-10-14 2018-10-12 Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения RU2771292C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
US62/572,467 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022111211A Division RU2022111211A (ru) 2017-10-14 2018-10-12 Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения

Publications (3)

Publication Number Publication Date
RU2020115713A RU2020115713A (ru) 2021-11-16
RU2020115713A3 RU2020115713A3 (https=) 2022-02-25
RU2771292C2 true RU2771292C2 (ru) 2022-04-29

Family

ID=64110112

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2020115713A RU2771292C2 (ru) 2017-10-14 2018-10-12 Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
RU2022111211A RU2022111211A (ru) 2017-10-14 2018-10-12 Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2022111211A RU2022111211A (ru) 2017-10-14 2018-10-12 Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения

Country Status (36)

Country Link
US (3) US20190111150A1 (https=)
EP (2) EP3691692B8 (https=)
JP (2) JP7374891B2 (https=)
KR (4) KR102385495B1 (https=)
CN (1) CN111278467B (https=)
AR (1) AR115178A1 (https=)
AU (1) AU2018346969A1 (https=)
BR (1) BR112020007302B1 (https=)
CA (1) CA3077730A1 (https=)
CL (1) CL2020000977A1 (https=)
CO (1) CO2020005685A2 (https=)
CR (1) CR20200206A (https=)
CY (1) CY1123968T1 (https=)
DK (1) DK3691692T3 (https=)
DO (1) DOP2023000150A (https=)
EC (1) ECSP20025198A (https=)
ES (1) ES2864013T3 (https=)
HR (1) HRP20210436T8 (https=)
HU (1) HUE054037T2 (https=)
IL (1) IL273586A (https=)
LT (1) LT3691692T (https=)
MA (1) MA50752B1 (https=)
MD (1) MD3691692T2 (https=)
MX (1) MX2020003723A (https=)
PE (1) PE20210125A1 (https=)
PH (1) PH12020550417A1 (https=)
PL (1) PL3691692T3 (https=)
PT (1) PT3691692T (https=)
RS (1) RS61596B1 (https=)
RU (2) RU2771292C2 (https=)
SG (1) SG11202003378WA (https=)
SI (1) SI3691692T1 (https=)
SM (1) SMT202100184T1 (https=)
TW (2) TW202330039A (https=)
UY (1) UY37931A (https=)
WO (1) WO2019075417A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
FI3635009T3 (fi) 2017-06-07 2026-04-07 Regeneron Pharma Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
RU2771292C2 (ru) * 2017-10-14 2022-04-29 Эббви Инк. Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
KR20220164773A (ko) * 2020-04-08 2022-12-13 앨리어다 테라퓨틱스, 인코포레이티드 혈액-뇌 장벽 전달용 조성물 및 방법
BR112022019841A2 (pt) * 2020-04-09 2022-12-06 Cytomx Therapeutics Inc Composições contendo anticorpos ativáveis
WO2022020108A1 (en) * 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof
IL318625A (en) * 2022-07-29 2025-03-01 Regeneron Pharma Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Novel anti-tfr1 (cd71) antibodies for cancer treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061996A2 (en) * 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2013115410A2 (en) * 2012-01-31 2013-08-08 Sbi Biotech Co., Ltd. Anti-phospholipase d4 antibody
EP2424891B1 (en) * 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Erg monoclonal antibodies
WO2016179257A2 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
RU2705367C2 (ru) * 2013-12-25 2019-11-07 Дайити Санкио Компани, Лимитед Конъюгат анти-trop2 антитело-лекарственное средство

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
WO2012104344A1 (en) * 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
RU2771292C2 (ru) * 2017-10-14 2022-04-29 Эббви Инк. Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061996A2 (en) * 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
EP2424891B1 (en) * 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Erg monoclonal antibodies
WO2013115410A2 (en) * 2012-01-31 2013-08-08 Sbi Biotech Co., Ltd. Anti-phospholipase d4 antibody
RU2705367C2 (ru) * 2013-12-25 2019-11-07 Дайити Санкио Компани, Лимитед Конъюгат анти-trop2 антитело-лекарственное средство
WO2016179257A2 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
MD3691692T2 (ro) 2021-05-31
DK3691692T3 (da) 2021-03-22
PE20210125A1 (es) 2021-01-19
PT3691692T (pt) 2021-03-29
WO2019075417A1 (en) 2019-04-18
EP3691692A1 (en) 2020-08-12
IL273586A (en) 2020-05-31
ECSP20025198A (es) 2020-06-30
EP3834846A1 (en) 2021-06-16
PH12020550417A1 (en) 2021-04-12
KR102529359B1 (ko) 2023-05-09
ES2864013T3 (es) 2021-10-13
MA50752B1 (fr) 2021-03-31
CN111278467B (zh) 2024-07-30
CO2020005685A2 (es) 2020-05-15
PL3691692T3 (pl) 2021-07-19
SG11202003378WA (en) 2020-05-28
DOP2023000150A (es) 2023-08-31
BR112020007302B1 (pt) 2023-01-31
CN111278467A (zh) 2020-06-12
LT3691692T (lt) 2021-05-10
KR20230004932A (ko) 2023-01-06
EP3691692B8 (en) 2021-05-26
RU2022111211A (ru) 2022-05-05
EP3691692B1 (en) 2020-12-30
KR20220045088A (ko) 2022-04-12
CA3077730A1 (en) 2019-04-18
TW202330039A (zh) 2023-08-01
JP2020537649A (ja) 2020-12-24
HUE054037T2 (hu) 2021-08-30
US20190111150A1 (en) 2019-04-18
KR20230070046A (ko) 2023-05-19
US20240115724A1 (en) 2024-04-11
SI3691692T1 (sl) 2021-04-30
KR20200070324A (ko) 2020-06-17
TWI780237B (zh) 2022-10-11
TW201927815A (zh) 2019-07-16
US20210145978A1 (en) 2021-05-20
JP2024012366A (ja) 2024-01-30
CR20200206A (es) 2021-02-18
AR115178A1 (es) 2020-12-09
BR112020007302A2 (pt) 2020-09-29
SMT202100184T1 (it) 2021-05-07
AU2018346969A1 (en) 2020-04-23
JP7374891B2 (ja) 2023-11-07
RU2020115713A3 (https=) 2022-02-25
UY37931A (es) 2019-04-30
HRP20210436T8 (hr) 2022-01-07
RS61596B1 (sr) 2021-04-29
KR102385495B1 (ko) 2022-04-15
HRP20210436T1 (hr) 2021-04-30
MA50752A (fr) 2020-08-12
RU2020115713A (ru) 2021-11-16
CY1123968T1 (el) 2022-05-27
MX2020003723A (es) 2020-07-22
CL2020000977A1 (es) 2020-09-11

Similar Documents

Publication Publication Date Title
RU2771292C2 (ru) Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
JP7781254B2 (ja) マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
JP7819160B2 (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
CN114478704B (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN114507283A (zh) 抗cd71抗体、可活化抗cd71抗体及其使用方法
AU2016257929A1 (en) Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
JP2016538240A (ja) マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
KR102958919B1 (ko) 매트릭스 메탈로프로테이스-절단성 기질 및 세린 또는 시스테인 프로테이스-절단성 기질 그리고 이들의 사용 방법
HK40025681B (en) Anti-cd71 activatable antibody drug conjugates and methods of use thereof
HK40025681A (en) Anti-cd71 activatable antibody drug conjugates and methods of use thereof